Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

(25.4 percent vs. 15.8 percent), erythema (24.6 percent vs. 18.4 percent), fever (10.3 percent vs. 8.6 percent), nausea (4.2 percent vs. 4.1 percent), pruritis (3.1 percent vs. 2.8 percent) and dizziness (2.8 percent vs. 2.6 percent).

Dosage and administration for GARDASIL

GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL should be administered in three separate intramuscular injections in the upper arm or upper anterior thigh over a six-month period. The following dosage schedule is recommended: first dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.

GARDASIL is widely available throughout the United States

There is broad private and public health insurance coverage for GARDASIL. Health plans covering approximately 98 percent of privately insured lives in the U.S. (currently more than 140 insurance plans) have implemented coverage for GARDASIL; however, individual benefit coverage and rates provided by health plans may vary.

GARDASIL was also added to the Vaccines for Children (VFC) Program on November 1, 2006, providing coverage for many who do not have private health insurance. All of the 55 immunization projects in the U.S. have adopted GARDASIL and most are filling provider orders.

Merck has also initiated a new patient assistance program for vaccines. Through this program, currently available in private physicians' offices and private clinics, Merck is making available, free of charge, GARDASIL and other Merck vaccines indicated for use in individuals ages 19 and older who are uninsured and who are unable to afford vaccines.

GARDASIL is approved in more than 70 countries

GARDASIL (sold in some countries as SILGARD(R)) has been approved in more than 70 countries, including the United States, the 27 countries of the European Union, Mexico, Australia, Taiwan, Canada, New Zealand and Brazil, and additional applications a
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

Post Your Comments:
(Date:11/25/2009)...PRNewswire/--PraxisElectronicMedicalRecordsreceive...sicians,(AAFP)FamilyPracticeManagement(FPM)2009EHR...ealthmaintenance,anddiseasemanagement,allcriticalf...ngdoctorsindicatingtheirEMRhadapositiveeffectindet...oneinthecountryinprovidingexcellenttrainingandsupp...
(Date:11/25/2009)...swire-FirstCall/--ERT(Nasdaq: ERES ),announcedtoda...CEO,andKeithSchneck,theCompany,sExecutiveVicePresi...erJaffrayHealthCareConferenceat1:30PMESTonDecember...esmayaccessthepresentationbyvisitingtheCompany,sco...alsobeaccessedat http://www.corporate-ir.net/ireye...
(Date:11/25/2009)...Newswire-USNewswire/--RemediumTechnologiesInc.,aco...rebleeding,wonfirstprizeand$10,000intheMostPromisi...2009,companyofficialsannouncetoday. ,, Selected...steampitchedtheirinventionattheGSCSecuritySummitco...edium( www.remediumtechnologies.com )isdevelopinga...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3More Than 5 000 Expected for Greater Chicago Food Depositorys 24th Annual Hunger Walk on Saturday June 20 at Montrose Harbor 49468 1More Than 5 000 Expected for Greater Chicago Food Depositorys 24th Annual Hunger Walk on Saturday June 20 at Montrose Harbor 49468 2American Dental Hygienists Association and Johnson 26 Johnson Healthcare Products Division of McNEIL PPC Inc Announce Honorees of HYGIENIST HERO 28 49463 1American Dental Hygienists Association and Johnson 26 Johnson Healthcare Products Division of McNEIL PPC Inc Announce Honorees of HYGIENIST HERO 28 49463 2American Dental Hygienists Association and Johnson 26 Johnson Healthcare Products Division of McNEIL PPC Inc Announce Honorees of HYGIENIST HERO 28 49463 3Lytix Biopharma and KAEL GemVax Announce Joint Clinical Trial to Combine LTX 315 and GV1001 Cancer Immunotherapy 12707 1Lytix Biopharma and KAEL GemVax Announce Joint Clinical Trial to Combine LTX 315 and GV1001 Cancer Immunotherapy 12707 2
...ed in study examining potential new ,GI-f... - Clinical results expected in second half o...rapeutics, Inc.,a privately held biopharmaceutical...lment in its two phase 3 trials HZ-CA-301 and HZ-C...nvestigational prescription NSAID,(non-steroidal a...
...acyclics,Inc. (Nasdaq: PCYC ) today announced pub...l highly-selective histone deacetylase (HDAC) inhi...ylase 8 (HDAC8)-specific inhibitor,PCI-34051 induc...February 7,issue of Leukemia., Histone deacetylas...naging a multitude of cellular functions. HDAC inh...
Other Medicine Technology:Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501 2Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501 3Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor 2Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor 3
(Date:11/26/2009)...mmunications announces a highly effective and unco...ruggling to make an economic recovery. , ...ears is the type of challenge that could send aili...to Dr. David Benton, business growth expert and au...– The Rfactor Intensive . “Fear is ...
(Date:11/25/2009)...swire/--TheBartleHallConventionCenterwilltemporari...whenKansasCityhoststhelatestinaseriesofmassivefree...enthasthepotentialtobethebiggestoneyet,becauseitwi...daysinsteadofoveraweekend,"SheriWood,executivedire...heNationalAssociationofFreeClinics(NAFC). ,, At...
(Date:11/25/2009)...SentinelleMedicalInc.,aleadingmanufacturerofbreast...uiteofnewleadingedgeclinicalapplicationsonitsAegis...ologicalSocietyofNorthAmerica(RSNA)annualmeetingin...icationsleveragetheuniquehighqualityimagesgenerate...tmultipleimagingmodalitiesformulti-parametricasses...
(Date:11/25/2009)...e-USNewswire/--TheBlackAIDSInstituterecentlyheldBo...ipfor2010. ,, ThenewBoardMembersareahighlydiver...finance,governmenthealthprograms,editorial,andbusi...geofpersonalbackgroundsincludingbothheterosexualan...ndrepresentingmultipleagegroups. ,, (Photo: htt...
(Date:11/25/2009)... cancer who were treated with cisplatin-based chem...eurological side effects and Raynaud-like phenomen..., according to a new study published online Novemb...tute . , Marianne Brydy, M.D., of the Department...rgen, Norway, and colleagues conducted a cross-sec...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...ason is the busiest shopping time of the year. In ...s on Black Friday weekend this year according to a...ually during this time, economists pay close atten...nality Continuum and Consumer Behavior, has taken ...
...Medical research has revealed much about cancer pr...icans, and are they acting on it" Today, at the A...ual International Conference on Frontiers in Cance... prevention science into public health policy. , ...
...r Relations Program Sets Stage for Increased Visib...vestors, CEDAR KNOLLS, N.J., Dec. 6 Emisphere,Te...that it has retained Adam,Friedman Associates, LLC...apeutic molecules and pharmaceutical,compounds usi...
...ation Focuses on Discovery of Small-Molecule Drugs...y, SOUTH PLAINFIELD, N.J., Dec. 6 PTC Therapeuti...d on the discovery, development,and commercializat...ular Atrophy (SMA) Foundation.,The collaboration b...
...6 - Atlantic Information,Services, Inc. (AIS) -- A...th Plan Week, Drug Benefit News and Specialty Phar...ts: Pharmacy Benefit Trends & Data. For the,past e...try. Trends revealed by this survey include the gr...
...uggest they might prevent cardiac arrest , ...s say they,re moving closer to using transplanted ...ring sudden cardiac arrest. , Working with mice, ...d study co-author Dr. Michael Kotlikoff, a profess...
Other Medicine News:Health News:Public health and cancer prevention: Success and future challenges in cancer policy 2Health News:Public health and cancer prevention: Success and future challenges in cancer policy 3Health News:Public health and cancer prevention: Success and future challenges in cancer policy 4Health News:Public health and cancer prevention: Success and future challenges in cancer policy 5Health News:Public health and cancer prevention: Success and future challenges in cancer policy 6Health News:Public health and cancer prevention: Success and future challenges in cancer policy 7Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 3Health News:PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation 2Health News:PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation 3Health News:2000-2007 Pharmacy Benefit Survey Results Just Released 2Health News:Cell Transplants Hold Promise for Heart Attack Survivors 2
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: